This company has been marked as potentially delisted and may not be actively trading. Bioverativ (BIVV) News Today Add Share Share Headlines Stock AnalysisBuy This Stock BIVV Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Bioverativ Aktie | BIVV Kurs | Realtime - Investing.comJuly 2, 2025 | de.investing.comBiogen Inc 0R1B Stock QuoteMay 25, 2023 | morningstar.comMEDU Crosses Above Average Analyst TargetApril 1, 2023 | nasdaq.comBioverativ Makes Splash in Trading Debut, Gaining 18% on Day OneDecember 17, 2022 | thestreet.comAmarin Stock: Potential Risks And Rewards (NASDAQ:AMRN) - Seeking AlphaAugust 14, 2022 | seekingalpha.comManagement to host conference call today at 4:30 p.m. ET - Form 8-K - Marketscreener.comAugust 5, 2022 | marketscreener.comMCuris Reports Second Quarter 2022 Financial Results and Business Update - Yahoo FinanceAugust 4, 2022 | finance.yahoo.comPrime Medicine Expands Leadership Team with Key Appointments to Support Continued Growth and Advancement of Prime Editing Technology and Portfolio - Yahoo FinanceJuly 28, 2022 | finance.yahoo.comPrime Medicine Expands Leadership Team with Key Appointments to Support Continued Growth and Advancement of Prime Editing Technology and Portfolio - Business WireJuly 28, 2022 | businesswire.comChancery Holding Amplifies Approach To Boardroom Issues - Law360July 21, 2022 | law360.comNeuron23 Appoints Kathy Dong, Pharm.D., MBA to Board of Directors - Yahoo FinanceJune 14, 2022 | finance.yahoo.comNo Toss For Del. Suit Targeting $11.6B Sanofi-Bioverativ Deal - Law360May 27, 2022 | law360.comPress Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1 - GlobeNewswireApril 28, 2022 | globenewswire.comGlobal Next Generation Complement Therapeutics Market Report 2022-2035: Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, RoA - ResearchAndMarkets.com - Business WireApril 4, 2022 | businesswire.comNuvalent Appoints Anna Protopapas as Chair of Board of Directors - PR NewswireApril 1, 2022 | prnewswire.comNuvalent Appoints Anna Protopapas as Chair of Board of Directors - Yahoo FinanceMarch 31, 2022 | finance.yahoo.comCold Agglutinin Disease Market to Exhibit Massive Growth at a CAGR of 28% in the 7MM for the Study Period of 2019-32 | DelveInsight - Yahoo FinanceMarch 30, 2022 | finance.yahoo.comWorldwide Gene Editing Beyond CRISPR Industry to 2035 - Featuring Amgen Ventures, ArrowMark Partners and Baxter Ventures Among Others - ResearchAndMarkets.com - Business WireMarch 21, 2022 | businesswire.comHormone Refractory Prostate Cancer Market Size [2022-2028] - GlobeNewswireMarch 19, 2022 | globenewswire.comHormone Refractory Prostate Cancer Market Size [2022-2028] to Reach USD 18.35 Billion and Exhibit a CAGR of 9.64% | The Brainy Insights - Yahoo FinanceMarch 17, 2022 | finance.yahoo.comSigilon Therapeutics (SGTX) Appoints Sarah Yuan as Chief Technical Operations Officer - StreetInsider.comFebruary 22, 2022 | streetinsider.comCrinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A. - Yahoo FinanceJanuary 5, 2022 | finance.yahoo.comRemedium Bio appoints Dr. Alexey Seregin as Vice President of Research and Development - PRNewswireNovember 30, 2021 | prnewswire.comRemedium Bio appoints Dr. Alexey Seregin as Vice President of Research and Development - StreetInsider.comNovember 29, 2021 | streetinsider.comThe Billionaire Chairman Of Vaccine Maker Moderna Wants To Reinvent Scientific Entrepreneurship - ForbesNovember 15, 2021 | forbes.commRNA Synthesis and Manufacturing Services Market Report 2021-2030 - GlobeNewswireOctober 12, 2021 | globenewswire.commRNA Synthesis and Manufacturing Services Markets, 2021-2030: Success of the Anti-COVID-19 Vaccines has Created an Enormous Need for Consistent Supply of These New Vaccines - PRNewswireOctober 12, 2021 | prnewswire.comGlobal Hemoglobinopathies Markets, 2021-2028 - High Unmet Needs / Increasing R&D Investment / Initiatives to Improve Disease Awareness - ResearchAndMarkets.com - Business WireOctober 5, 2021 | businesswire.comFulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer - StreetInsider.comSeptember 8, 2021 | streetinsider.comBioTheryX Announces Appointments of Three New Members to its Board of Directors - PRNewswireAugust 8, 2021 | prnewswire.comBioTheryX Announces Appointments of Three New Members to its Board of Directors - Markets InsiderAugust 8, 2021 | markets.businessinsider.comBiogen: Q2 Earnings Insights - BenzingaJuly 22, 2021 | benzinga.com Get Bioverativ News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVV and its competitors with MarketBeat's FREE daily newsletter. Email Address BIVV Media Mentions By Week BIVV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIVV News Sentiment▼0.000.54▲Average News Sentiment BIVV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIVV Articles This Week▼00▲BIVV Articles Average Week Get Bioverativ News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIVV) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioverativ Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioverativ With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
